Adam, Awadalkareem
Kalveram, Birte
Chen, John Yun-Chung
Yeung, Jason http://orcid.org/0000-0002-4202-9771
Rodriguez, Leslie
Singh, Ankita
Shi, Pei-Yong http://orcid.org/0000-0001-5553-1616
Xie, Xuping http://orcid.org/0000-0003-0918-016X
Wang, Tian http://orcid.org/0000-0002-1511-0793
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI127744, AI176670)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS125778)
U.S. Department of Health & Human Services | National Institutes of Health (HHSN272201600013C)
Sealy & Smith Foundation and the Kleberg Foundation
Article History
Received: 17 March 2023
Accepted: 26 September 2023
First Online: 20 October 2023
Competing interests
: The Shi laboratory has received funding support in sponsored research agreements from Pfizer, Gilead, Novartis, GSK, Merck, IGM Biosciences, and Atea Pharmaceuticals. P.Y.S. is a member of the Pfizer COVID Antiviral Medical Board, a member of the Scientific Advisory Board of AbImmune, and a founder of FlaviTech. X.X. and P.-Y.S. have filed a patent on the live-attenuated SARS-CoV-2. The other authors declare that there are no competing interests.